Novozymes A/S (OTCMKTS:NVZMY) Stock Crosses Below Two Hundred Day Moving Average – What’s Next?

Shares of Novozymes A/S (OTCMKTS:NVZMY) crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $60.87 and traded as low as $57.91. Novozymes A/S shares last traded at $59.45, with a volume of 45,662 shares.

Analyst Ratings Changes

Several research firms have recently commented on NVZMY. Zacks Research cut shares of Novozymes A/S from a “hold” rating to a “strong sell” rating in a report on Monday, May 4th. Rothschild & Co Redburn raised Novozymes A/S to a “strong-buy” rating in a research report on Friday, March 27th. Finally, Kepler Capital Markets raised shares of Novozymes A/S from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, May 13th. Two research analysts have rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy”.

Novozymes A/S Trading Up 1.1%

The company has a fifty day simple moving average of $58.72 and a two-hundred day simple moving average of $60.87. The company has a debt-to-equity ratio of 0.12, a current ratio of 0.72 and a quick ratio of 0.44. The company has a market capitalization of $24.92 billion, a P/E ratio of 40.61, a price-to-earnings-growth ratio of 1.11 and a beta of 0.98.

Novozymes A/S (OTCMKTS:NVZMY) last released its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.51 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.82 by ($0.31). Novozymes A/S had a return on equity of 6.57% and a net margin of 14.22%.The company had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.32 billion. On average, analysts forecast that Novozymes A/S will post 2.43 earnings per share for the current fiscal year.

About Novozymes A/S

Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.

The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).